Cerebrospinal fluid assay
    36.
    发明授权

    公开(公告)号:US10174361B2

    公开(公告)日:2019-01-08

    申请号:US14357475

    申请日:2012-11-12

    Abstract: The present invention is directed to methods of isolating particles, such as nucleic acid-containing particles or microvesicles, from a biological sample and extracting nucleic acids therefrom, wherein the biological sample is cerebrospinal fluid. The present invention further provides methods for aiding diagnosis, prognosis, monitoring and evaluation of a disease or other medical condition in a subject by detecting a biomarker associated with a disease or medical condition thereof.

    Urine Biomarkers
    38.
    发明申请
    Urine Biomarkers 审中-公开
    尿液生物标志物

    公开(公告)号:US20150024949A1

    公开(公告)日:2015-01-22

    申请号:US14508603

    申请日:2014-10-07

    CPC classification number: C12Q1/6886 C12Q2600/106 C12Q2600/118 C12Q2600/158

    Abstract: A method for detecting biomarkers of prostate cancer or other medical condition of the prostate based on the use of microvesicles obtained from urine samples, and the nucleic acids present in the microvesicles. The method disclosed herein are advantageous in that they may be used to support diagnosis, prognosis, monitoring, or therapy selection in lieu of or in conjunction with traditional biopsy-based diagnostics and do not require a digital rectal examination or prostate massage prior to urine sample collection.

    Abstract translation: 基于从尿样获得的微泡的使用以及存在于微泡中的核酸,检测前列腺癌的生物标志物或前列腺的其它医学状况的方法。 本文公开的方法的优点在于它们可用于支持诊断,预后,监测或治疗选择,以代替传统的基于活检的诊断结合或结合传统的基于活检的诊断,并且不需要在尿液样本之前进行直肠指诊或前列腺按摩 采集。

Patent Agency Ranking